A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours.
AuthorsKhan, O A
Lorigan, Paul C
Watson, Amanda J
Thorncroft, Mary R
Margison, Geoffrey P
Middleton, M R
AffiliationUniversity of Oxford Department of Oncology, Churchill Hospital, Old Road, Oxford OX3 7LJ, UK.
MetadataShow full item record
AbstractPoly adenosine diphosphate (ADP)-ribose polymerase (PARP) is essential in cellular processing of DNA damage via the base excision repair pathway (BER). The PARP inhibition can be directly cytotoxic to tumour cells and augments the anti-tumour effects of DNA-damaging agents. This study evaluated the optimally tolerated dose of olaparib (4-(3--4-fluorophenyl) methyl-1(2H)-one; AZD2281, KU0059436), a potent PARP inhibitor, with dacarbazine and assessed safety, toxicity, clinical pharmacokinetics and efficacy of combination treatment.
CitationA phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours. 2011, 104 (5):750-5 Br. J. Cancer
JournalBritish Journal of Cancer
PubMed Central IDPMC3048218